324 related articles for article (PubMed ID: 28025473)
1. [Target Therapy in Unresectable or Metastatic Colorectal Cancer].
Kim JH; Park SJ
Korean J Gastroenterol; 2016 Dec; 68(6):303-311. PubMed ID: 28025473
[TBL] [Abstract][Full Text] [Related]
2. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
Derangère V; Fumet JD; Boidot R; Bengrine L; Limagne E; Chevriaux A; Vincent J; Ladoire S; Apetoh L; Rébé C; Ghiringhelli F
Oncotarget; 2016 Feb; 7(8):9309-21. PubMed ID: 26824184
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
4. Current and advancing treatments for metastatic colorectal cancer.
Sanz-Garcia E; Grasselli J; Argiles G; Elez ME; Tabernero J
Expert Opin Biol Ther; 2016; 16(1):93-110. PubMed ID: 26549053
[TBL] [Abstract][Full Text] [Related]
5. Precision Medicine in Metastatic Colorectal Cancer: Relevant Carcinogenic Pathways and Targets-PART 1: Biologic Therapies Targeting the Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor.
Weinberg BA; Hartley ML; Salem ME
Oncology (Williston Park); 2017 Jul; 31(7):539-48. PubMed ID: 28712098
[TBL] [Abstract][Full Text] [Related]
6. Selection of biologics for patients with metastatic colorectal cancer: the role of predictive markers.
Kasi PM; Hubbard JM; Grothey A
Expert Rev Gastroenterol Hepatol; 2015 Mar; 9(3):273-6. PubMed ID: 25579664
[TBL] [Abstract][Full Text] [Related]
7. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy in advanced colorectal cancer: more data, more questions.
Ochenduszko SL; Krzemieniecki K
Anticancer Drugs; 2010 Sep; 21(8):737-48. PubMed ID: 20631611
[TBL] [Abstract][Full Text] [Related]
9. The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer.
Van Cutsem E; Geboes K
Best Pract Res Clin Gastroenterol; 2007; 21(6):1089-108. PubMed ID: 18070705
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
Köhne CH; Lenz HJ
Oncologist; 2009 May; 14(5):478-88. PubMed ID: 19411318
[TBL] [Abstract][Full Text] [Related]
11. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab in the treatment of patients with colorectal cancer.
Garrett CR; Eng C
Expert Opin Biol Ther; 2011 Jul; 11(7):937-49. PubMed ID: 21557708
[TBL] [Abstract][Full Text] [Related]
13. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
Venook AP
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S74-84. PubMed ID: 19780248
[TBL] [Abstract][Full Text] [Related]
14. Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy.
Engstrom PF;
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):18S-22S. PubMed ID: 18980548
[TBL] [Abstract][Full Text] [Related]
15. Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials.
Khattak MA; Martin H; Davidson A; Phillips M
Clin Colorectal Cancer; 2015 Jun; 14(2):81-90. PubMed ID: 25666296
[TBL] [Abstract][Full Text] [Related]
16. The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
García-Alfonso P; Grande E; Polo E; Afonso R; Reina JJ; Jorge M; Campos JM; Martínez V; Angeles C; Montagut C
Angiogenesis; 2014 Oct; 17(4):805-21. PubMed ID: 24793846
[TBL] [Abstract][Full Text] [Related]
17. First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405.
Elez E; Argilés G; Tabernero J
Curr Treat Options Oncol; 2015 Nov; 16(11):52. PubMed ID: 26374340
[TBL] [Abstract][Full Text] [Related]
18. Role of targeted agents in metastatic colorectal cancer.
Prenen H; Vecchione L; Van Cutsem E
Target Oncol; 2013 Jun; 8(2):83-96. PubMed ID: 23645285
[TBL] [Abstract][Full Text] [Related]
19. [Monoclonal antibodies therapies for colorectal cancer: cétuximab, panitumumab and bevacizumab].
Piront P; Van Daele D; Belaiche J; Polus M
Rev Med Liege; 2009; 64(5-6):274-8. PubMed ID: 19642458
[TBL] [Abstract][Full Text] [Related]
20. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
Patel DK
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):31S-41S. PubMed ID: 18980550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
